Introduction to Female Pelvic Medicine and Reconstructive Surgery (FPMRS)
Almost one out of every four women suffers from at least one type of pelvic floor disorder—urinary incontinence, anal incontinence, or pelvic organ prolapse. With the problem only expected to grow, pelvic floor disorders represent a major public health concern in the United States.
As providers who work with women, you play an important role in starting the conversation with your patients, asking questions, and effectively identifying, recognizing and evaluating these disorders. Each course in this three online course series focuses on one specific type of pelvic floor disorder. The series can be purchased together or as individual courses, and can be completed on your schedule.
Enhance your knowledge of pelvic floor disorders with the most up-to-date information to diagnose these medical conditions in your patients.
Who Should Enroll
This course is designed for primary care physicians, primary care residents, allied health professionals, and other specialists who regularly provide care to women.
What You Will Learn Should
- To explain the prevalence and impact of urinary incontinence, identify the common types, explain bladder function, diagnose urinary incontinence in patients, and apply common treatment options;
- To conduct effective patient evaluations and recognize the psychological, social, and sexual impact of anal incontinence; evaluate the relationships between current medications and anal incontinence; explain the effects of vaginal childbirth, aging, obesity, health habits, and pelvic surgery on lower GI tract function; correctly diagnose anal incontinence; and apply non-surgical techniques to prevent and treat anal incontinence; and
- To differentiate pelvic organ prolapse (POP) from normal vaginal support; identify the most specific symptoms; diagnose POP in your patients; and select the best surgical or non-surgical treatment options.
Click here to get started!
Click here to view the course in our FPMRS Education Portal.
Please note: to purchase the course, you will be instructed to create a free guest account. Click here to create your guest account.
Continuing Medical Education
The Duke University School of Medicine designates this online educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM per course.
Course Release Date: January 1, 2012
Course Expiration Date: December 31, 2013
Estimated time to Complete: One hour per module
Take advantage of the special introductory price (available only for a limited time):
- $25 per online course
- $50 for the 3-course series
Staff and Content Validation Reviewer Disclosure
The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.
Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
Planning Committee/Faculty Disclosure
The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CME activity.
Anna Marie Connolly, MD; Gary Sutkin, MD; John Fischer, MD; Gara Grimes, MD; Brittney Hampton, MD
The following speakers and/or planning committee members have indicated that they have relationship(s) with industry to disclose:
Rachel Pauls, MD – fulfills the role as Consultant for American Medical Systems; as a research for BioSante Pharmaceuticals; as a Advisory Board Member of Viveve Inc.
Lily Arya, MD – fulfills the role Principal Investigator for Pfizer
John Jelovsek, MD – fulfills the role as Advisory Board Member for Bayer Pharmaceuticals
Leslie Rickey, MD – fulfills the role as Principal Investigator for Pfizer; as a Consultant for Johnson & Johnson
Unapproved Use Disclosure
Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will not be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.